Pharmaceutical manufacturers can use AI to build custom operational software for procurement and material planning, approved vendor status and audit calendars, packaging component inventory, plant and utility maintenance scheduling, campaign and capacity planning, dispatch and distribution, distributor stock visibility, near-expiry channel stock, sales returns and export documentation. Pentoggle is an AI platform that generates production-ready software from a plain English description, which means a pharmaceutical company can build the operational layer around its regulated systems rather than replacing anything that sits inside them.
Most pharmaceutical manufacturers already run validated systems for manufacturing and quality records, and Tally or SAP Business One for accounting. Those systems handle what they were built for, and in the case of the validated system, what your licence requires. This is not a proposal to replace either of them. Pentoggle builds the surrounding operational application around them, covering the workflows they were never designed for.
Key takeaways
- The validated system is designed to protect the product, and it was never designed to run the commercial operation around it.
- Approved vendor status is a calendar problem, and purchase orders get placed on vendors whose qualification has quietly lapsed.
- Packaging components are usually the constraint on a campaign, not manufacturing capacity.
- Near-expiry stock sitting with stockists is a predictable loss that becomes visible only when it returns.
- The number that runs the operational side of a pharmaceutical business is the value of channel stock within a defined window of expiry.
What this page does not cover
Being explicit is more useful here than in any other industry. Pentoggle is not a GMP system and should not be used for anything that belongs inside your validated environment. That includes batch manufacturing records and electronic batch records, the quality management system, deviation and incident management, corrective and preventive action, change control, equipment and process validation, computerised system validation and any release decision.
Those functions belong where they already are, in systems that have been qualified for the purpose and that your regulator and your auditors expect to see. Nothing on this page is a substitute for any of them.
What remains outside that boundary is substantial, and it is largely unserved. Procurement, vendor status tracking, maintenance calendars, distribution, channel stock and returns are business operations. They are not GMP functions, they are usually run on spreadsheets, and they are where a great deal of money is lost in Indian pharmaceutical companies.
A note on regulatory scope
Pharmaceutical manufacturing in India is licensed and regulated, and the systems, records and controls a site must maintain are defined by its licence, the applicable schedules and the requirements of any market it supplies. Pentoggle applications hold operational business records only, outside the validated environment, as described above. They are not validated systems, they do not carry GMP status, and they do not certify compliance with anything. Confirm the boundary for your site with your quality head, your regulatory affairs team and your legal advisor before any deployment.
Why the operational layer is usually a spreadsheet
A pharmaceutical company invests heavily in the systems its licence requires, and correctly so. The quality system, the batch records and the documentation around them receive attention, budget and audit scrutiny.
Everything outside that boundary tends to receive whatever is left. Purchase follows up by email. The approved vendor list is a document somebody maintains. Maintenance schedules for utilities and non-critical plant sit in a diary. Distributor stock is known when the distributor reports it, which is usually when they want a credit note. Export documentation is assembled per consignment.
This is not carelessness. It is a reasonable allocation of attention toward the things that carry regulatory consequence. But the operational layer carries commercial consequence, and in most companies nobody has ever been given the tools to see it.
The comparison below covers only the operational layer, outside the validated environment.
What pharmaceutical companies use today, and what they can build instead
| Spreadsheets and email | ERP where present | Application built with Pentoggle | |
|---|---|---|---|
| Approved vendor status | A document, updated when remembered | Vendor master without status dates | Status with expiry and audit due dates, visible to purchase |
| Packaging components | Followed up per campaign | Shortage reported per item | Readiness per planned campaign |
| Maintenance scheduling | Diary and reminders | Plant maintenance module, often unused | Calendar with due dates and completion records |
| Campaign planning | Planned in a meeting | Production orders | Capacity and component readiness against the plan |
| Distributor stock | Reported when convenient | Not visible | Stock and ageing where distributors report it |
| Near-expiry channel stock | Discovered on return | Not modelled | Visible by product and stockist, months ahead |
| Returns | Processed as credit notes | Sales return | Linked to batch and stockist, with reason and age |
What a pharmaceutical company can build
Each of these can be built separately or combined. Most companies start with vendor status and channel stock visibility.
Approved vendor register
Vendors with their approval status, the materials they are approved for, audit dates, requalification due dates and current standing, visible to whoever raises a purchase order.
Procurement and material planning
Requirements against planned campaigns, order status and expected receipt dates.
Packaging component inventory and readiness
Cartons, foils, labels, inserts, bottles and closures by product, with readiness shown against the campaign schedule.
Plant and utility maintenance scheduling
Preventive maintenance calendars for utilities and equipment, with due dates, assignment and completion records held as business records outside the validated environment.
Campaign and capacity planning
What is planned to run when, against available capacity and component readiness.
Dispatch and distribution
Consignments to carrying and forwarding agents, stockists and distributors, with the documentation each requires.
Distributor stock visibility
Stock held downstream where distributors report it, with ageing by product and batch.
Near-expiry monitoring
Channel stock approaching expiry, by product, batch and stockist, surfaced early enough to act on.
Returns handling
Returns received, linked to their batch and stockist, with reason, age and the commercial treatment applied.
Export documentation
The commercial documentation a consignment requires, assembled from records rather than typed per shipment.
Approved vendor status is a calendar nobody owns
A material vendor is qualified, audited and approved. That approval has a validity, an audit cycle and conditions. The information lives in a quality document.
The purchase order is raised somewhere else, by someone working from a vendor master and a price. The connection between the two is a person remembering, and people are reliable until they are on leave, or until the vendor list has grown past what anyone can hold in their head.
What follows is an ordinary administrative failure with a serious consequence: material ordered from a vendor whose approval has lapsed, discovered at receipt, at audit, or worse. The material is fine. The paperwork is not, and in a regulated business the paperwork is the point.
Making status and dates visible where the order is raised removes the dependency on memory. Approved for these materials, status current until this date, audit due on this date. It is one of the simplest things on this page and one of the most consequential, because it converts a recurring risk into a field on a screen.
The same logic extends to contract testing laboratories, contract manufacturers and any other qualified third party whose status expires on a calendar somebody has to watch.
Campaigns are constrained by components, not by capacity
A campaign is planned. The granulation, compression and coating capacity exists. The active pharmaceutical ingredient is available. And the campaign does not start, because the printed foil for one pack size has not arrived or the cartons are on their previous artwork version.
Packaging components in pharmaceuticals are product specific, often print specific, subject to their own controls, and sourced from a limited set of approved suppliers with real lead times. Any one of them missing stops a campaign as completely as a missing active would.
Readiness across the campaign schedule is the view that helps: which planned campaigns can actually start, which are blocked, and by what. That is a different report from a list of short items, and it is the one a planner can act on. It also prevents the more expensive version of the problem, where bulk is manufactured and then waits, occupying quarantine space and consuming its own hold time while a component is chased.
Expiry in the channel is a predictable loss treated as a surprise
Product leaves your plant with a shelf life. It sits with a carrying and forwarding agent, then a stockist, then a retailer. Somewhere in that chain, a portion of it does not sell in time.
In most companies the first sign of this is a return: expired or near-expiry stock coming back, with a credit note attached, quarter after quarter. It is treated as a cost of doing business and provisioned for, which makes it a number in a budget rather than a problem with a cause.
It is highly predictable. Stock that entered the channel eight months ago with an eighteen month shelf life, sitting with a stockist whose offtake is known, will come back. Knowing that in month eight rather than month sixteen creates options that do not exist later: redistribution to a territory with faster movement, a promotion, or simply not shipping more of the same product into a channel that is already saturated.
Making channel stock and its ageing visible requires cooperation from distributors, which is the real work. But the reporting itself is not complex, and companies that have this visibility make quite different distribution decisions from those that do not.
Why building this is now practical
Operational software for the layer around the validated environment has never been a priority purchase. Validated systems consume the budget and the attention, ERP implementations are large and slow, and the remaining workflows are handled by capable people with spreadsheets.
With Pentoggle you describe how your operations run, including your vendor qualification process, your campaign planning, your distribution structure and what your distributors report, and get a working application. When you add a market, change a distribution arrangement, or need channel ageing reported monthly, you describe the change and the application updates. Most companies start with approved vendor status and channel stock visibility, because those two carry risk and money respectively.
Because everything here sits outside the validated environment, the deployment question is a business one rather than a validation exercise. Where you are unsure whether a particular workflow crosses the boundary, treat it as inside and leave it where it is.
Why pharmaceutical companies choose Pentoggle
Clear boundary
Nothing built inside the validated environment, and the exclusions stated rather than implied.
Built around your operations
Your vendor process, your campaign structure, your distribution network.
Works alongside your existing systems
The validated system stays, accounting stays, and the operational layer stops being a spreadsheet.
Visibility into the channel
Ageing and near-expiry stock surfaced while there is still time to act.
Changes in days
A new market or a new distributor reporting format does not become a three month project.
The one number that runs the operational side
The value of channel stock within a defined window of expiry.
Choose the window from your shelf life and your distribution cycle, commonly six or nine months remaining. Then track the value of stock in the channel that has crossed it, by product and by stockist.
Every rupee on that list is a loss that has not happened yet and can still be prevented. Once it becomes a return it is a credit note, a destruction cost and a product that was manufactured for nothing. Reviewed monthly, the list also shows which products are being pushed into the channel faster than they move, which is a distribution decision rather than a warehouse problem.
Ready to build operational software for your plant?
The validated system protects the product. It was never meant to run the business around it.